Avanos Medical (AVNS)
(Delayed Data from NYSE)
$22.80 USD
+0.15 (0.66%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $22.81 +0.01 (0.04%) 5:16 PM ET
1-Strong Buy of 5 1
B Value D Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$22.80 USD
+0.15 (0.66%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $22.81 +0.01 (0.04%) 5:16 PM ET
1-Strong Buy of 5 1
B Value D Growth C Momentum C VGM
Zacks News
Here's Why You Should Retain Catalent (CTLT) Stock for Now
by Zacks Equity Research
Catalent's (CTLT) product and service launches and a slew of strategic deals raise optimism about the stock.
Three Reasons to Add BD (BDX) Stock to Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about BD (BDX) owing to a few regulatory approvals and product launches.
Here's Why You Should Retain Surmodics (SRDX) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.
Walgreens Boots (WBA) Benefits From New Launches Amid FX Woes
by Zacks Equity Research
Walgreens Boots' (WBA) comparable pharmacy sales decline, reflecting lower demand for COVID-19 services.
Humana (HUM) Ties Up To Offer Value-Based Care to MA Members
by Zacks Equity Research
Humana (HUM) inks a 10-year collaboration with Aledade to ensure continued value-based primary care to its Medicare Advantage members from Aledade-backed physicians.
NextGen (NXGN) Behavioral Health Suite Adopted by Compass Health
by Zacks Equity Research
NextGen's (NXGN) Behavioral Health Suite is expected to aid Compass Health in improving its workflow.
Should Value Investors Buy Avanos Medical (AVNS) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
SmileDirectClub (SDC) Q4 Earnings Beat, Gross Margin Down
by Zacks Equity Research
SmileDirectClub (SDC) delivers an improved bottom line and cash flows in the fourth quarter despite a reduction in revenues.
Community Health (CYH) to Divest Two NC Hospitals for $320M
by Zacks Equity Research
Community Health (CYH) expects the North Carolina hospitals' divestment to close at a later part of this year.
Humana (HUM), CD&R Backed Gentiva to Buy Assets From ProMedica
by Zacks Equity Research
The acquisition is expected to boost Humana (HUM) and CD&R backed Gentiva's reach to over 500 locations.
Omnicell (OMCL) Q4 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Omnicell (OMCL) delivers earnings and revenues in the fourth quarter exceeding the previously revised outlook amid macroeconomic challenges.
Acadia Healthcare (ACHC) Q4 Earnings Miss on Rising Costs
by Zacks Equity Research
Acadia Healthcare's (ACHC) 2023 capital expenditure for expansion initiatives is predicted to stay between $350 million and $400 million.
Alcon (ALC) Q4 Earnings Match Estimates, Margins Contract
by Zacks Equity Research
Alcon (ALC) reports impressive CER growth in net sales across all segments in the fourth quarter amid a challenging macroeconomic environment.
PerkinElmer's (PKI) Latest Launch to Boost Research Workflows
by Zacks Equity Research
PerkinElmer's (PKI) latest launch is expected to provide increased assay flexibility to researchers.
Reasons to Add Quest Diagnostics (DGX) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Quest Diagnostics (DGX) on its accelerated growth strategy and improvements in base volumes.
BD's (BDX) New FDA Approval to Improve Cervical Cancer Testing
by Zacks Equity Research
BD's (BDX) receipt of the latest FDA approval is likely to improve the detection and prevention of cervical cancer.
What Makes Avanos Medical (AVNS) a New Buy Stock
by Zacks Equity Research
Avanos Medical (AVNS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Avanos (AVNS) Q4 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Avanos' (AVNS) fourth-quarter 2022 results reflect strength in both segments.
Avanos Medical (AVNS) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of 25% and 1.11%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
3 Beaten-Down MedTech Stocks Poised for a Turnaround in 2023
by Debanjana Dey
Here are some dirt-cheap MedTech value stocks - DYNT, INGN, AVNS - which are expected to provide long-term gains.
3 Reasons to Retain Avanos (AVNS) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.
Avanos Medical (AVNS) Up 21% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Avanos (AVNS) Q3 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Avanos' (AVNS) third-quarter 2022 results reflect strength in the Pain Management segment.
Avanos Medical (AVNS) Tops Q3 Earnings Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of 5.56% and 1.79%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?